Business Context and Reporting Period
This Form 8-K was filed by OncoGenex Pharmaceuticals, Inc. on February 25, 2016. The report addresses a regulatory notice received from The NASDAQ Stock Market, LLC regarding the company's listing status on The NASDAQ Capital Market.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on compliance with listing standards rather than financial performance metrics.
Material Changes
The material change reported is the receipt of a written notice from NASDAQ indicating non-compliance with Listing Rule 5550(a)(2), which mandates a minimum bid price of $1.00 per share for continued listing. This notice was received on February 25, 2016.
Outlook, Risks, and Contingencies
- Compliance Period: The company has 180 calendar days, until August 23, 2016, to regain compliance.
- Requirements: To regain compliance, the closing bid price must meet or exceed $1.00 per share for a minimum of ten consecutive business days within the 180-day window.
- Secondary Compliance Period: If the company fails to comply by August 23, 2016, it may be afforded a second 180-day period. Qualification for this extension requires meeting the market value of publicly held shares and all other initial listing standards, excluding the minimum bid price requirement.
- Remedial Actions: The company may implement a reverse stock split to cure the deficiency.
- Risks: There is no assurance the company will regain compliance. Failure to do so within allotted periods will result in delisting. The company retains the right to appeal a delisting determination to a NASDAQ Listing Qualifications Panel.
Investor Verification Checklist
- Verify the current closing bid price of OncoGenex Pharmaceuticals, Inc. common stock relative to the $1.00 threshold.
- Monitor the company's stock price for ten consecutive business days to assess progress toward compliance.
- Check for subsequent filings regarding the implementation of a reverse stock split.
- Review the company's market value of publicly held shares to determine eligibility for a potential second compliance period.